Celyad SA (Belgium) Today
| CYAD Stock | EUR 0.65 0.04 5.80% |
Performance11 of 100
| Odds Of DistressLess than 17
|
Celyad SA is selling at 0.65 as of the 22nd of November 2024; that is 5.8% down since the beginning of the trading day. The stock's lowest day price was 0.65. Celyad SA has less than a 17 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Celyad SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. The company has 22.59 M outstanding shares. More on Celyad SA
Moving against Celyad Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Celyad Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Celyad SA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Celyad SA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Filippo Petti |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Celyad SA (CYAD) is traded on Euronext Brussels in Belgium and employs 95 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Celyad SA's market, we take the total number of its shares issued and multiply it by Celyad SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Celyad SA operates under Biotechnology sector and is part of Health Care industry. The entity has 22.59 M outstanding shares.
Celyad SA has accumulated about 12.13 M in cash with (26.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Celyad SA Probability Of Bankruptcy
Ownership AllocationCelyad SA holds a total of 22.59 Million outstanding shares. Celyad SA shows 8.83 percent of its outstanding shares held by insiders and 24.19 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Celyad Ownership Details
Celyad SA Risk Profiles
Although Celyad SA's alpha and beta are two of the key measurements used to evaluate Celyad SA's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 7.43 | |||
| Semi Deviation | 6.99 | |||
| Standard Deviation | 14.95 | |||
| Variance | 223.47 |
Celyad Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Celyad SA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Celyad SA Corporate Directors
| Jaak Minten | Director Clinical Affairs, representing Fakkel SPRL | Profile | |
| Roland GordonBeresford | Regulatory Affairs and IP Director | Profile | |
| William Wijns | Non-Executive Director, permanent representative of the Cardiovascular Center Aalst CVBA | Profile | |
| Hanspeter Spek | Non-Executive Director | Profile |
Additional Tools for Celyad Stock Analysis
When running Celyad SA's price analysis, check to measure Celyad SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celyad SA is operating at the current time. Most of Celyad SA's value examination focuses on studying past and present price action to predict the probability of Celyad SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celyad SA's price. Additionally, you may evaluate how the addition of Celyad SA to your portfolios can decrease your overall portfolio volatility.